TIMELINE FOR ABSTRACT SUBMISSION | ||
---|---|---|
Registration Type | Regular Registration | |
Date : 31 May 2025 | Abstract submission deadline | |
Date : 1 June - 31 August 2025 | Abstract review and revision period | |
Date : 31 August 2025 | Abstract acceptance confirmed via email | |
Date : 31 October 2025 | Deadline for submitting oral presentation files and poster files |
Research topics The 4th JoPPP-Thailand 2025 invites research abstracts in pharmacy and medicinal sciences. Abstracts will be accepted for oral and poster presentations under the following six topics:
Slide preparation
Poster preparation
Best Oral presentation wards
1.Policy and regulation
2.Clinical and pharmacy practice
3.Health and medical sciences
Best Poster presentation wards
1.Policy and regulation
2.Clinical and pharmacy practice
3.Health and medical sciences
Rationale (Clarity and Significance of Purpose)
5: The rationale is exceptionally clear, compelling, and addresses a highly significant problem or question.
4: The rationale is clear and addresses an important problem or question.
3: The rationale is somewhat clear but lacks full articulation of significance.
2: The rationale is unclear or addresses a minor problem or question.
1: The rationale is poorly stated, irrelevant, or absent.
Methodologies (Appropriateness and Detail)
5: Methodology is exceptionally well-detailed, appropriate, and rigorous for the research question.
4: Methodology is clearly explained, appropriate, and generally rigorous.
3: Methodology is moderately clear and appropriate but lacks detail or rigor.
2: Methodology is vague or not entirely appropriate for the research question.
1: Methodology is poorly described, inappropriate, or absent.
Accuracy of Data Analysis
5: Data analysis is accurate, thorough, and well-matched to the research question. Results are clearly presented and meaningful.
4: Data analysis is accurate and relevant but could benefit from additional detail or clarity.
3: Data analysis is mostly accurate but may contain minor errors or inconsistencies.
2: Data analysis contains significant errors, inconsistencies, or lack of clarity.
1: Data analysis is absent, incorrect, or inappropriate for the research.
Implications (Relevance to Pharmaceutical Policy and Practice)
5: Implications are exceptionally well-articulated, demonstrating clear and significant relevance to advancing pharmaceutical policy and practice.
4: Implications are clearly stated and provide meaningful contributions to pharmaceutical policy and practice.
3: Implications are somewhat clear and relevant but lack depth or strong connections to pharmaceutical policy and practice.
2: Implications are unclear, have limited relevance, or are weakly connected to pharmaceutical policy and practice.
1: Implications are irrelevant, insignificant, or fail to address pharmaceutical policy and practice.
Novelty (Originality and Innovation)
5: The abstract demonstrates exceptional originality and introduces innovative ideas or approaches.
4: The abstract is original and includes some innovative aspects.
3: The abstract is moderately original but lacks significant innovation.
2: The abstract has limited originality or relies heavily on previously established ideas.
1: The abstract lacks originality and does not present any new ideas or perspectives.